AbbVie stock weekly forecast: support at $254.34 under scrutiny as sellers press recent lows

Traders Union
All News
Stocks
AbbVie slips 2.56% this week

Highlights

Shares of AbbVie declined 2.56% over the past 7 days to $258.54, trending at the low edge of their recent range.
Technical indicators send mixed signals with a buy from MACD, overbought signals from Bull/Bear Power, and a sell from HMA.
Next week, AbbVie stock is forecast to consolidate between $253.23 and $265.05, with a 77% probability of an increase if resistance at $260.31 is broken.

Guidance boosts outlook as new product growth offsets legacy declines

ABBV reported strong second-quarter 2026 earnings, with revenue rising 10.2% to $16.99 billion and adjusted diluted EPS up 22.9% to $3.65, as reported by www.ad-hoc-news.de and confirmed by Seeking Alpha and Yahoo Finance. Growth from Skyrizi and Rinvoq offset a sharp drop in Humira sales, supporting sentiment for the upcoming week. The company lifted its full-year 2026 EPS guidance and maintained a $1.73 quarterly dividend, while releasing new clinical data for investigational lung cancer therapies at the 2026 World Conference on Lung Cancer, according to PR Newswire.

Mixed technical signals deepen as price tests key weekly boundaries

On the daily chart, the backdrop is a developing trend with volatility at 2.53%, as the stock has moved sharply to the lower edge of its recent range. While the MACD gives a buy forecast and Bull/Bear Power signals overbought conditions, HMA issues a sell call, indicating a lack of full momentum confirmation. $254.34, the Ichimoku Kijun level, now marks the nearest support, while resistance sits at $260.31. This mix of signals and the current momentum character—a developing, unconfirmed move lower—suggests that a clearer direction could emerge with a break of either boundary.

Trend confirmation hinges on resistance breakout or support breach next week

Next week, AbbVie stock is expected to trade between $253.23 and $265.05. The probability of an increase stands at 77%, versus a 23% chance of a decrease. The base case is consolidation within this range, with the trend’s confirmation hinging on a break of $260.31 to the upside or $254.34 to the downside. Above resistance, further gains may follow, while a dip below support would tilt the near-term risk lower.

Anton Kharitonov, expert at Traders Union, points out that AbbVie stock saw a nearly 3% decline this week, testing the lower edge of its recent range as recovery efforts look increasingly fragile. He notes that while robust Q2 2026 earnings and raised EPS guidance offered some support, the technical indicators remain conflicted. On the chart, signals show a developing yet unconfirmed downside move, with the MACD buy call countered by weakness from the HMA and overbought Bull/Bear Power readings. Support at $254.34 and resistance at $260.31 will be critical markers for the week ahead. The probability still leans toward a range-bound scenario, but sector sentiment is mixed and momentum lacks clear conviction. "Unless AbbVie sustains price above $260.31, I remain cautious and prefer to wait for a decisive break in either direction."

Earlier, analysts noted that AbbVie's technical momentum and regulatory advancements positioned the stock for potential further gains. The recent mix of strong earnings and product updates now introduces additional catalysts, with a conclusive directional move likely to be confirmed by a break above $260.31 resistance or below $254.34 support.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.